HRP20201893T1 - Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura - Google Patents

Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura Download PDF

Info

Publication number
HRP20201893T1
HRP20201893T1 HRP20201893TT HRP20201893T HRP20201893T1 HR P20201893 T1 HRP20201893 T1 HR P20201893T1 HR P20201893T T HRP20201893T T HR P20201893TT HR P20201893 T HRP20201893 T HR P20201893T HR P20201893 T1 HRP20201893 T1 HR P20201893T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
formula
aliphatic
use according
image
Prior art date
Application number
HRP20201893TT
Other languages
English (en)
Croatian (hr)
Inventor
Scott J. Weir
Shrikant Anant
Original Assignee
The University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Kansas filed Critical The University Of Kansas
Publication of HRP20201893T1 publication Critical patent/HRP20201893T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20201893TT 2014-11-11 2015-11-10 Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura HRP20201893T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462078069P 2014-11-11 2014-11-11
US201562134747P 2015-03-18 2015-03-18
PCT/US2015/059955 WO2016077346A1 (en) 2014-11-11 2015-11-10 Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug
EP15859268.3A EP3217980B1 (en) 2014-11-11 2015-11-10 Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
HRP20201893T1 true HRP20201893T1 (hr) 2021-02-05

Family

ID=55954945

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201893TT HRP20201893T1 (hr) 2014-11-11 2015-11-10 Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura

Country Status (11)

Country Link
US (1) US20170304329A1 (https=)
EP (1) EP3217980B1 (https=)
JP (1) JP2017533952A (https=)
CN (2) CN116687941A (https=)
DK (1) DK3217980T3 (https=)
ES (1) ES2836208T3 (https=)
HR (1) HRP20201893T1 (https=)
HU (1) HUE052670T2 (https=)
PT (1) PT3217980T (https=)
RS (1) RS61222B1 (https=)
WO (1) WO2016077346A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112351970A (zh) * 2018-05-30 2021-02-09 科莱恩国际有限公司 2-羟基吡啶-1-氧化物或其衍生物的形成方法
CN113194945B (zh) * 2018-08-23 2024-07-23 佩勒梅德有限公司 环吡酮的抑制hbv核心组装的用途
WO2021078937A1 (en) * 2019-10-25 2021-04-29 Deutsches Krebsforschungszentrum Treatment of stat3 related diseases by iron chelators
EP4193989A1 (en) 2021-12-09 2023-06-14 Atlas Molecular Pharma, S.L. A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
US20110212176A1 (en) 2008-10-31 2011-09-01 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
EP2576513A1 (en) * 2010-06-01 2013-04-10 Biotheryx Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
JP5853028B2 (ja) * 2010-12-02 2016-02-09 カンザス大学 ６−シクロヘキシル−１−ヒドロキシ−４−メチルピリジン−２（１ｈ）−オンのプロドラッグおよびその誘導体

Also Published As

Publication number Publication date
WO2016077346A1 (en) 2016-05-19
HUE052670T2 (hu) 2021-05-28
EP3217980A4 (en) 2018-05-02
CN107206012A (zh) 2017-09-26
US20170304329A1 (en) 2017-10-26
PT3217980T (pt) 2020-12-11
CN116687941A (zh) 2023-09-05
RS61222B1 (sr) 2021-01-29
JP2017533952A (ja) 2017-11-16
ES2836208T3 (es) 2021-06-24
DK3217980T3 (da) 2020-12-07
EP3217980B1 (en) 2020-10-14
EP3217980A1 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2017180917A3 (en) Lipid compositions and their uses for intratumoral polynucleotide delivery
HRP20201893T1 (hr) Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura
ZA202508806B (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
HRP20210342T1 (hr) Pripravci glikopeptida
ZA201900694B (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CA2999253C (en) Heterocyclic compounds and uses thereof
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
EA201891099A1 (ru) 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7
EA201791717A1 (ru) Стабильные водные составы адалимумаба
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
PH12022550007A1 (en) Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
AR100684A1 (es) Imidas de bajo peso molecular que contienen sales de amonio cuaternario
EA201791733A1 (ru) Производные 9h-пирролодипиридина
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
MX384798B (es) Piridinona dicarboxamida para uso como inhibidores de bromodominio.
MX386216B (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
EA201992679A1 (ru) N-замещенные индольные производные
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
RU2019119405A (ru) Лиофилизированные фармацевтические композиции далбаванцина
WO2018160178A8 (en) Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EA201992382A2 (ru) Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
MX2015016429A (es) Moduladores del receptor cxcr7.